PT866720E - Proteina ob para aumentar a massa do tecido mole - Google Patents

Proteina ob para aumentar a massa do tecido mole

Info

Publication number
PT866720E
PT866720E PT96938773T PT96938773T PT866720E PT 866720 E PT866720 E PT 866720E PT 96938773 T PT96938773 T PT 96938773T PT 96938773 T PT96938773 T PT 96938773T PT 866720 E PT866720 E PT 866720E
Authority
PT
Portugal
Prior art keywords
protein
increase mass
mole
increasing
tissue
Prior art date
Application number
PT96938773T
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Francis Toombs
Michael Benjamin Mann
Mary Ann Pelleymounter
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT866720E publication Critical patent/PT866720E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96938773T 1995-11-22 1996-11-04 Proteina ob para aumentar a massa do tecido mole PT866720E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
PT866720E true PT866720E (pt) 2004-06-30

Family

ID=24243198

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96938773T PT866720E (pt) 1995-11-22 1996-11-04 Proteina ob para aumentar a massa do tecido mole

Country Status (15)

Country Link
EP (3) EP0956862A1 (cg-RX-API-DMAC7.html)
JP (2) JP4173914B2 (cg-RX-API-DMAC7.html)
AT (2) ATE259243T1 (cg-RX-API-DMAC7.html)
AU (3) AU7607496A (cg-RX-API-DMAC7.html)
CA (2) CA2358862A1 (cg-RX-API-DMAC7.html)
DE (2) DE69638119D1 (cg-RX-API-DMAC7.html)
DK (1) DK0866720T3 (cg-RX-API-DMAC7.html)
ES (2) ES2339846T3 (cg-RX-API-DMAC7.html)
IL (2) IL124442A0 (cg-RX-API-DMAC7.html)
MX (1) MX9803992A (cg-RX-API-DMAC7.html)
NZ (3) NZ512083A (cg-RX-API-DMAC7.html)
PT (1) PT866720E (cg-RX-API-DMAC7.html)
SI (1) SI0866720T1 (cg-RX-API-DMAC7.html)
WO (1) WO1997018833A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA969605B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0917469A1 (en) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Methods for inducing bone formation
RS49927B (sr) * 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
PT1151102E (pt) * 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
BR112013007385B1 (pt) 2010-09-28 2022-07-26 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
HUE042196T2 (hu) 2013-11-26 2019-06-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
AU7535394A (en) * 1993-08-13 1995-03-14 Putzmeister-Werk Maschinenfabrik Gmbh Process and device for treating the surface of large objects
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
CZ9802013A3 (cs) * 1995-12-27 1998-09-16 Genentech, Inc. Deriváty OB proteinu, chimerní OB polypeptidy, prostředky pro léčbu obezity a dalších fyziologických stavů a způsob léčení těmito prostředky, kódující sekvence pro OB protein, expresní vektor nesoucí tuto sekvenci, buňky transformované tímto vektorem a způsob jejich kultivace, a způsob navození růstu buněk s pomocí OB proteinu
RS49927B (sr) * 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法

Also Published As

Publication number Publication date
SI0866720T1 (en) 2004-10-31
ATE455554T1 (de) 2010-02-15
DK0866720T3 (da) 2004-06-14
EP0866720A1 (en) 1998-09-30
CA2236163A1 (en) 1997-05-29
DE69631544D1 (de) 2004-03-18
IL124442A0 (en) 1998-12-06
ES2217327T3 (es) 2004-11-01
DE69638119D1 (de) 2010-03-11
AU763769B2 (en) 2003-07-31
IL127926A (en) 2006-08-20
MX9803992A (es) 1998-09-30
IL127926A0 (en) 1999-11-30
JP4173914B2 (ja) 2008-10-29
NZ512083A (en) 2003-02-28
EP1285664A3 (en) 2003-07-30
JP2000500492A (ja) 2000-01-18
JP4227325B2 (ja) 2009-02-18
ATE259243T1 (de) 2004-02-15
ZA969605B (en) 1997-06-02
AU4265200A (en) 2000-09-21
AU763755B2 (en) 2003-07-31
EP0866720B1 (en) 2004-02-11
EP1285664A2 (en) 2003-02-26
AU4265300A (en) 2000-09-07
JP2002206000A (ja) 2002-07-23
EP1285664B1 (en) 2010-01-20
CA2358862A1 (en) 1997-05-29
ES2339846T3 (es) 2010-05-26
EP0956862A1 (en) 1999-11-17
WO1997018833A1 (en) 1997-05-29
DE69631544T2 (de) 2004-12-23
NZ527007A (en) 2005-01-28
AU7607496A (en) 1997-06-11
NZ511617A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
PT866720E (pt) Proteina ob para aumentar a massa do tecido mole
EA200100053A1 (ru) Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат
GR3030141T3 (en) Diphtheria toxin receptor-binding region.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
FR2784282B1 (fr) Systeme d'osteosynthese rachidienne a rigidite amelioree
DE69500014D1 (de) Widerlager zur Klammerung von weichem Gewebe
LU91411I2 (fr) Panitumumab et ses dérivés pharmaceutiquement acceptables (VECTIBIX)
DE69621260D1 (de) Biokompatible hydrophile gleitmittel fur medizinische instrumente
EA199800946A1 (ru) Концентрированный препарат антител
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DE69626152D1 (de) Chirurgisches Nähinstrument
SE9500566L (sv) L-platta
EA199700155A1 (ru) Ингибиторы тромбина
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
ATE342970T1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
NO974322D0 (no) DNA som koder for human papillomvirus type 18
BR0200571A (pt) Produtos de legumes
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
IL113940A0 (en) Novel elastase inhibitors
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
ATE248218T1 (de) Humane hypertrophe chrondrozyten zelllinien